Insilico Medicine and SK Biopharmaceuticals Enter $2.5 Billion AI-Based CNS Drug Co-Development Agreement
Recovery and Renewed Confidence in the Global Bio-Investment Market
With the 2026 Shanghai DIA China and San Diego BIO International Convention as key milestones, confidence is returning to global biotech companies. In fact, the number of deals in the first quarter of 2026 recorded the highest level since 2023, increasing by approximately 2 times year-on-year. This revitalization reflects the demand for securing portfolios in anticipation of the major 'Patent Cliff' facing large pharmaceutical companies in 2030. Despite remaining market risks, investors' willingness to deploy capital is confirmed, opening up new opportunities for growth.
The Rise of Chinese Biotech and Diversification of Global Regulatory Pathways
One of the most notable trends at this convention was the remarkable growth of pipelines in the Asia-Pacific (APAC) region, led by China. Chinese biotech companies account for 23% of the global new drug pipeline, employing a '3F Strategy' of 'First in China,' 'First in Human,' and 'First in Class.' It is estimated that more than two-thirds of the total deal value in 2026 will be attributable to Chinese assets, demonstrating its growing dominance. Although there are uncertainties due to U.S. trade regulations, the company is expanding its global presence by diversifying its approval pathways through the European Medicines Agency (EMA) and other regulatory bodies.
The Insilico and SK Biopharmaceuticals Mega-Deal Signals the Realization of AI-Based Drug Development
The $2.5 billion co-R&D agreement between Insilico Medicine and SK Biopharmaceuticals, announced at BIO 2026, demonstrates that AI-based drug development is translating into tangible results. By combining Insilico's AI platform, Pharma.AI, with SK Biopharmaceuticals' clinical capabilities, the companies will develop new drug candidates for central nervous system (CNS) and neuro-immune diseases. While AI-based drug development in the past relied on marketing, it is now becoming a practical tool for reducing development costs and timelines. This deal is a benchmark case that demonstrates the synergy when technological credibility and commercial potential are combined.
Diversification of Clinical Portfolios and Capital Efficiency as Survival Strategies
The trend among global biotech companies shows that oncology-centric portfolios are gradually diversifying, decreasing from 42% in 2023 to 30% in 2025. Instead, neurology, immunology, cardiometabolic diseases, and obesity treatments are emerging as new key areas. In particular, obesity treatments (GLP-1) are undergoing technological advancements, such as improved oral formulations and sustained-release formulations. Investors are no longer simply enthusiastic about early data but prioritize 'Capital Efficiency' by efficiently allocating limited resources and demonstrating a proven commercialization roadmap.
In a rapidly growing global CNS therapeutics market, valued at $190 billion by 2025, the $2.5 billion AI-based CNS drug development agreement between Insilico Medicine and SK Biopharmaceuticals represents a pivotal event that demonstrates the potential for AI platform technology to translate into substantial mega-deals. In the short term, the use of Insilico's Pharma.AI platform to accelerate target identification and candidate optimization will enhance R&D efficiency and significantly reduce early-stage development cost risks. In the medium to long term, SK Biopharmaceuticals, with its global clinical capabilities, will take charge of late-stage development and global commercialization, increasing the likelihood of FDA approval for both biologics and small molecule candidates. This will enhance the value of assets in the Asia-Pacific (APAC) region, which accounts for 23% of the global pipeline, and serve as an opportunity to narrow the gap with global Big Pharma companies such as Eli Lilly (LLY) and Novo Nordisk (NVO) in the CNS and obesity (GLP-1) treatment areas, moving away from an oncology-centric approach. As a result, the valuation attractiveness of biotech companies that demonstrate capital efficiency and partnership capabilities is expected to increase further among venture capital (VC) and institutional investors.